There is support for pneumococcal vaccines, with research suggesting that two doses may provide comparable long-term protection to three doses. The market for pneumococcal vaccines is expected to grow, with projected revenue reaching a significant amount by 2034. Various organizations, including government agencies and health alliances, are involved in efforts related to vaccine support and immunization programs.